| Lori Jill Zimmerman, DO | |
|
605 N Walnut Street, North Manchester, IN 46962 | |
| (260) 982-1994 | |
| Not Available |
| Full Name | Lori Jill Zimmerman |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 605 N Walnut Street, North Manchester, Indiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457395006 | NPI | - | NPPES |
| 200238120 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 02002097A (Indiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lori Jill Zimmerman, DO 6920 Pointe Inverness Way Ste 200, Fort Wayne, IN 46804-7934 Ph: (260) 479-3513 | Lori Jill Zimmerman, DO 605 N Walnut Street, North Manchester, IN 46962 Ph: (260) 982-1994 |
News Archive
When teenagers receive health education and information about contraception, the number of them having unintended pregnancies decreases, finds a large new review.
A new study finds that higher nurse staffing levels can lead to better patient outcomes. However, the study also found this to not always be the case at safety net hospitals. Meanwhile, the Connecticut Mirror reports on hospitals' efforts to reduce readmissions. And, in other news, new research has found that patients are less likely to fill prescriptions when doctors specify brand names instead of allowing generic substitutions.
Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, today announced that the first patient has been treated in a Phase 2 clinical trial of intravenous treatment with JX-594 for patients with advanced hepatocellular carcinoma (HCC), or liver cancer, who have not received treatment with sorafenib—the current standard of care for this patient population.
New diagnosis guidelines for autism spectrum disorder (ASD) issued by the American Psychiatric Association (APA) may reduce by almost one third the total number of people being diagnosed, according to new research from Columbia University School of Nursing published in the Journal of Autism and Developmental Disorders.
AbbVie, a global biopharmaceutical company, today announced that results from a Phase 1b trial of investigational venetoclax, a novel inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, in combination with bortezomib and dexamethasone, showed an 83 percent overall response rate (n=5/6) in bortezomib-naive patients with relapsed/refractory (R/R) multiple myeloma, including two patients who achieved complete responses.1 These data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, May 31, in Chicago.
› Verified 7 days ago
Shelly Prichard, NP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 605 N Walnut St, North Manchester, IN 46962 Phone: 260-982-1994 | |
Dr. Joy Elizabeth Struble, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 605 N. Walnut Street, North Manchester, IN 46962 Phone: 260-982-1994 Fax: 260-982-9274 | |
Kelly Louise Mullen, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 605 N Walnut St, North Manchester, IN 46962 Phone: 260-982-1994 Fax: 260-479-2936 |